H.-Christian von Büdingen
H.-Christian von Büdingen
Verified email at
Cited by
Cited by
Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial
AJ Green, JM Gelfand, BA Cree, C Bevan, WJ Boscardin, F Mei, J Inman, ...
The Lancet 390 (10111), 2481-2489, 2017
Long‐term evolution of multiple sclerosis disability in the treatment era
University of California, San Francisco MS‐EPIC Team:, BAC Cree, ...
Annals of neurology 80 (4), 499-510, 2016
Comparison of intraarterial and intravenous thrombolysis for ischemic stroke with hyperdense middle cerebral artery sign
HP Mattle, M Arnold, D Georgiadis, C Baumann, K Nedeltchev, ...
Stroke 39 (2), 379-383, 2008
Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients
A Palanichamy, S Jahn, D Nickles, M Derstine, A Abounasr, SL Hauser, ...
The Journal of Immunology 193 (2), 580-586, 2014
B cell exchange across the blood-brain barrier in multiple sclerosis
HC von Büdingen, TC Kuo, M Sirota, CJ Van Belle, L Apeltsin, J Glanville, ...
The Journal of clinical investigation 122 (12), 4533-4543, 2012
Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation
J Glanville, TC Kuo, HC von Büdingen, L Guey, J Berka, PD Sundar, ...
Proceedings of the National Academy of Sciences 108 (50), 20066-20071, 2011
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis
A Palanichamy, L Apeltsin, TC Kuo, M Sirota, S Wang, SJ Pitts, ...
Science translational medicine 6 (248), 248ra106-248ra106, 2014
Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery
F Mei, K Lehmann-Horn, YAA Shen, KA Rankin, KJ Stebbins, DS Lorrain, ...
Elife 5, e18246, 2016
Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis
PH Lalive, T Menge, C Delarasse, B Della Gaspera, D Pham-Dinh, ...
Proceedings of the National Academy of Sciences 103 (7), 2280-2285, 2006
Spinal cord gray matter atrophy correlates with multiple sclerosis disability
R Schlaeger, N Papinutto, V Panara, C Bevan, IV Lobach, M Bucci, ...
Annals of neurology 76 (4), 568-580, 2014
Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients
D Georgiadis, M Arnold, HC Von Buedingen, P Valko, H Sarikaya, ...
Neurology 72 (21), 1810-1815, 2009
Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination
HCV Bũdingen, N Tanuma, P Villoslada, JC Ouallet, SL Hauser, ...
Journal of clinical immunology 21, 155-170, 2001
B lymphocytes in neuromyelitis optica
JL Bennett, KC O'Connor, A Bar-Or, SS Zamvil, B Hemmer, TF Tedder, ...
Neurology-Neuroimmunology Neuroinflammation 2 (3), 2015
Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity
O Stüve, S Youssef, MS Weber, S Nessler, HC von Büdingen, B Hemmer, ...
The Journal of clinical investigation 116 (4), 1037-1044, 2006
B cells in multiple sclerosis: connecting the dots
HC von Büdingen, A Bar-Or, SS Zamvil
Current opinion in immunology 23 (6), 713-720, 2011
Frontline: Epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination
HC von Büdingen, SL Hauser, JC Ouallet, N Tanuma, T Menge, ...
European journal of immunology 34 (8), 2072-2083, 2004
Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin‐specific antibodies
HC von Büdingen, MD Harrer, S Kuenzle, M Meier, N Goebels
European journal of immunology 38 (7), 2014-2023, 2008
Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination
HC von Büdingen, SL Hauser, A Fuhrmann, CB Nabavi, JI Lee, ...
Proceedings of the National Academy of Sciences 99 (12), 8207-8212, 2002
Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis
R Schlaeger, N Papinutto, AH Zhu, IV Lobach, CJ Bevan, M Bucci, ...
JAMA neurology 72 (8), 897-904, 2015
Disease-modifying agents for multiple sclerosis: recent advances and future prospects
T Menge, MS Weber, B Hemmer, BC Kieseier, HC von Büdingen, ...
Drugs 68, 2445-2468, 2008
The system can't perform the operation now. Try again later.
Articles 1–20